Fingerprint
Dive into the research topics of 'A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically